Anti-IFI44 antibody

• WB

Supplier Data

Western blot - Anti-IFI44 antibody (AB172499)

All lanes:

Western blot - Anti-IFI44 antibody (ab172499) at 1 µg/mL

Lane 1:

IFI44-transfected 293T cell lysate at 15 µL

Lane 2:

Non-transfected 293T cell lysate at 15 µL

Secondary

All lanes:

Goat Anti-Rabbit IgG (H+L) at 1/7500 dilution

Predicted band size: 50 kDa

true

• WB

CiteAb

Western blot - Anti-IFI44 antibody (AB172499)

IFI44 western blot using anti-IFI44 antibody ab172499. Publication image and figure legend from DeDiego, M. L., Nogales, A., et al., 2019, MBio, PubMed 31455651.

ab172499 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab172499 please see the product overview.

IFI44 is induced by IFN treatment and IAV infection. (A) Human 293T cells were transfected with the pCAGGS plasmid expressing IFI44-HA protein (left) or treated with 150 or 750 U/ml of universal type I IFN for 12 h (right). Western blot was performed using anti-IFI44 (top) and actin (bottom) antibodies. Western blots were quantified by densitometry using ImageJ software (v1.46), and the amounts of IFI44 were normalized to the amounts of actin (numbers below the IFI44 blot). N.D., not detected. Molecular weight markers are indicated (in kilodaltons) on the right. Three different experiments were performed, with similar results. (B) Human A549 cells were infected with influenza PR8 virus at an MOI of 0.1. Total RNAs were collected at 24, 48, and 72 hpi, and the level of expression of IFI44 was evaluated by RT-qPCR and compared to the level seen with noninfected cells (0 hpi). Error bars represent standard deviations (SD) of results of measurements performed in triplicate wells. *, p < 0.05 (for comparisons between results measured for infected cells at 24, 48, and 72 hpi and those measured for noninfected cells [0 hpi] using Student's t test).

false